Technology Listings

Gedunin for Treating Neurodegenerative Diseases


Gedunin and its derivatives for the treatment of Parkinson's disease, Alzheimer's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, stroke, and Huntington's disease.

Technical Summary

The invention comprises gedunin derivatives for the treatment of neurological disorders. These compounds are TrkB agonists, and mimic the action of the natural ligand, brainderived neurotrophic factor (BDNF). TrkB is a receptor tyrosine kinase (RTK) with high affinity for neurotrophins, polypeptide growth factors responsible for neuronal differentiation and survival via signal transduction cascades. Decreased levels of the neurotrophin BDNF has been implicated in a number of neurological disorders. Administration of exogenous neurotrophins can stimulate nerve growth and survival, but is hampered by the poor drug-like qualities of the compound including instability, poor bioavailability, and low levels of brain penetration. Synthetic peptides which mimic various domains of BDNF stimulate neuronal growth, but have not been shown to operate via a TrkB-dependent mechanism. In addition, large polypeptides with high molecular weights (ca. 2000) traditionally have proved difficult to develop with clinical success. The inventor has shown a significant reduction of infarct volume following 5 mg/kg intraperitoneal injection of deoxygedunin (38%) versus vehicle (65%) in the middle cerebral artery occlusion model in rats.


Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Nationalized PCT - United States United States 13/056,377 8,203,009 7/28/2009 6/16/2012 7/28/2029
Nationalized PCT - Foreign EP 09803483.8   2/28/2011    
Nationalized PCT - Foreign China 200980137217.4 ZL 2009 8 0137217.4 3/22/2011 7/17/2013 7/28/2029
Divisional United States 13/479,653 8,609,870 5/24/2012 12/17/2013 11/21/2029
Tech ID: 08013
Published: 3/26/2009

Cliff Michaels
Assistant Director
Emory University

Keqiang Ye